(Reuters) -Savara on Wednesday said its experimental drug,molgramostim, met the main goal of a late-stage trial for treating a rare lung disease characterized by a feeling of breathlessness.
The drug developer’s inhaled drug showed statistically significant improvement in a measure called Diffusing Capacity of the Lungs for Carbon Monoxide (DCLO) in patients compared to placebo at week 24.
DCLO measures the lungs’s ability to transfer gas from inhaled air to red blood cells in pulmonary capillaries.
The trial tested molgramostim in treating adult patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
(Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid)
Brought to you by www.srnnews.com
